

July 20, 2017

NEWS RELEASE**For Immediate Release
START UP MATERIALS SECURED FOR PRODUCTION**

Vancouver, B.C., July 20, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“**Umbral or Company**”) on behalf of the management of PhyeinMed Inc. (“PhyeinMed”), a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations), announces that it has signed an agreement with CanGenX BioTech Inc. (CanGenX) to undertake plant tissue culture as its production basis.

CanGenX provides advanced production technologies to the legal medical cannabis industry. PhyeinMed expects that applied science can be used to gain a competitive edge in this newly regulated marketplace. This is done using ‘tissue culture micro-propagation’, which can take one plant and multiply it into thousands within a few months. allowing PhyeinMed to take its best performing plants and replicate them to fill their entire production system. The intended result is to create genetically uniform, robust, and disease-free starting plant material, and thereby eliminating traditional propagating methods which are subject to genetic variability, reduced germination and survival rates, and can contain disease. CanGenX facilitates the supply of high volume tissue culture starter plants in house with the purpose of permitting PhyeinMed to produce the safest cannabis possible.

Debra Senger, CEO of PhyeinMed states “we are excited to move forward with CanGenX as we expect it to deliver us many benefits including uniformity of crop, quicker propagation and a savings of cost and time in production. In this new competitive market, we are aiming to be a quality producer while focusing on optimizing returns in our operations.”

In addition, CanGenX will consult on the set up a propagation lab facility as well as supplying proprietary strain-specific media to PhyeinMed on demand.

About Umbral Energy Corp.

The Company is currently listed as a junior resource issuer having mineral exploration projects. The Company is considering other activities to increase shareholder value, including non-resource projects. The Company has a mineral exploration project in Quebec. In addition the Company has a 75% interest in PhyeinMed, a Health Canada late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations).

ON BEHALF OF THE BOARD OF DIRECTORS OF UMBRAL ENERGY CORP.*“Jag Bal”*

Jagdip Bal
President and CEO

UMBRAL ENERGY CORP.
929 Mainland Street, Vancouver, BC V6B 1S3
Tel: (604) 628-1767 | Fax: (604) 628-0129
info@umbralenergy.com | www.umbralenergy.com

The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

